Nurix Therapeutics Inc（NRIX）の株式分析NRIXNurix Therapeutics Inc

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nurix Therapeutics Inc appears to be a good buy right now due to its recent collaboration with Roche, which has significantly boosted its financial outlook with an upfront payment of $700 million and potential milestone payments up to $2.3 billion. The current price of $26.21 is well below the analyst price targets, with Morgan Stanley setting a target of $38, indicating a potential upside of 45%. Additionally, the stock has shown a strong year-to-date change of +45.13%, reflecting positive market sentiment. However, the main risk is the negative net income reported, which was -89,535,000 USD in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.